ContraFect Corporation (NASDAQ:CFRX) is scheduled to be issuing its quarterly earnings data on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.
ContraFect Corporation (NASDAQ:CFRX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. On average, analysts expect ContraFect Corporation to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ContraFect Corporation (NASDAQ:CFRX) opened at $1.02 on Friday. ContraFect Corporation has a 1-year low of $0.80 and a 1-year high of $2.70.
COPYRIGHT VIOLATION NOTICE: “ContraFect Corporation (CFRX) Scheduled to Post Quarterly Earnings on Tuesday” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/11/05/contrafect-corporation-cfrx-scheduled-to-post-quarterly-earnings-on-tuesday.html.
ContraFect Corporation Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
What are top analysts saying about ContraFect Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ContraFect Corporation and related companies.